Clinical Trial Detail

NCT ID NCT01145430
Title Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer
Recruitment Completed
Gender female
Phase Phase I
Variant Requirements yes
Sponsors National Cancer Institute (NCI)
Indications

Her2-receptor negative breast cancer

peritoneal carcinoma

ovary epithelial cancer

fallopian tube carcinoma

Therapies

pegylated liposomal doxorubicin + Veliparib

Age Groups: adult

Additional content available in CKB BOOST